Hormone Therapy for Cancer vs HRT: Same Words, Opposite Goals

The phone call came from her sister: ‘Wait, they put you on hormone therapy? Isn’t that what caused it?’ She had spent the afternoon in an oncology clinic learning that the small tablet she would take each morning was designed to starve her breast cancer of estrogen. Her sister was thinking of the patch she wore for hot flashes. Two treatments, one shared word, and a family conversation that went sideways in under a minute.

That confusion is not a failing of patients. Medicine really does use the phrase hormone therapy for two interventions with opposite aims, and the debate over hormone therapy for cancer vs HRT is muddied further by headlines that lump every hormone into one risk bucket.

This explainer separates them cleanly: what each does inside the body, who is usually offered which, what the risk numbers actually show, and the questions worth bringing to your next appointment.

Hormone therapy for cancer vs HRT: what each one actually does

Picture a thermostat. HRT turns the heat up in a house that has gone cold; hormone therapy for cancer turns it down in a room that is overheating. Both touch the same dial. The intent could not be more different.

Hormone replacement therapy, also called menopausal hormone therapy, gives back estrogen after the ovaries have stopped producing it in meaningful amounts. Estrogen is the hormone that, among many jobs, stabilizes the body’s temperature control and keeps vaginal and urinary tissue supple. Anyone with a uterus usually takes a progestogen alongside it, a hormone that keeps the womb lining from thickening under unopposed estrogen (Mayo Clinic).

Hormone therapy for cancer, sometimes called endocrine therapy, does the reverse. Some tumors carry hormone receptors, molecular docking stations on the cell surface that let estrogen or testosterone act as a growth signal. Endocrine therapy either blocks the docking station, stops the body from making the hormone, or both. The tumor loses a fuel line it depended on (NCI).

Why this matters day to day: the side effects run in opposite directions too. HRT often relieves hot flashes and vaginal dryness. Cancer hormone therapy frequently causes them, because it deliberately creates a low-estrogen or low-testosterone state. A person told they are ‘on hormones’ after a breast cancer diagnosis is almost always being deprived of a hormone, not given one.

One more distinction is worth fixing in mind early. HRT is a comfort and quality-of-life treatment for a normal life stage. Endocrine therapy is a cancer treatment with the goal of lowering the chance the disease returns or slowing it where it has spread. The bar for accepting side effects is different, and so is the conversation with the prescriber.

How hormone therapy for cancer works, and which cancers it targets

Not every cancer listens to hormones. The two that most often do are breast cancer and prostate cancer, with some endometrial (womb lining) cancers also responding (NCI).

For breast cancer, the first step happens in the pathology lab, not the pharmacy. A sample of the tumor is tested for estrogen receptors and progesterone receptors. If either is present, the cancer is called hormone receptor positive, and endocrine therapy becomes an option. If both are absent, blocking hormones would achieve nothing, so it is not offered (NCI).

Three broad mechanisms are used, described here by drug class rather than as recommendations:

• Selective estrogen receptor modulators, such as tamoxifen, sit in the receptor so estrogen cannot. They work before or after menopause.
• Aromatase inhibitors block aromatase, the enzyme that converts other hormones into estrogen in fat and muscle tissue. After menopause this is the main estrogen source, so these drugs are mainly used in postmenopausal women or alongside ovarian suppression (NCI).
• Ovarian suppression uses injections, or occasionally surgery, to switch off ovarian estrogen production in premenopausal women.

For prostate cancer the target is testosterone, an androgen. Androgen deprivation therapy lowers testosterone to very low levels, usually with injections that signal the testicles to stop producing it, sometimes combined with tablets that block the androgen receptor (NCI).

Timing is described with two words. Adjuvant means given after surgery to reduce the chance of recurrence; the NCI notes adjuvant endocrine therapy for breast cancer is typically continued for 5 to 10 years. Neoadjuvant means given before surgery to shrink a tumor. In advanced disease the aim shifts to control rather than prevention, and treatment may continue as long as it keeps working and is tolerated. Those durations are guideline ranges, and your oncologist tailors them to the specific tumor.

What HRT does for menopause, and what it does not do

Menopause is confirmed after 12 months without a period, and the years around it can bring hot flashes, night sweats, sleep disruption, mood changes, joint aches and vaginal dryness. HRT is the most effective treatment for the vasomotor symptoms, the medical term for flushing and sweating driven by a confused temperature thermostat (NHS).

It comes in two families. Systemic HRT enters the bloodstream through tablets, skin patches, gels or sprays and treats symptoms throughout the body. Local vaginal estrogen, delivered as a cream, pessary or ring, works mainly on the tissue it touches, with very little absorbed elsewhere; it treats dryness, discomfort with sex and some urinary symptoms but does not reliably help hot flashes (Mayo Clinic).

The other axis is estrogen-only versus combined. Estrogen-only HRT is usually reserved for people who have had a hysterectomy. Combined HRT adds a progestogen to protect the womb lining. That single ingredient turns out to matter a great deal for breast cancer risk, which a later section unpacks (Lancet 2019 meta-analysis).

What HRT is not: it is not an anti-aging treatment, it is not a general protection against heart disease when started later in life, and it is not a substitute for bone, heart and cancer screening. Mayo Clinic summarizes current guidance as follows: for healthy people with bothersome symptoms who start before age 60 or within 10 years of menopause, benefits generally outweigh risks; starting later, or with certain histories, changes that calculation.

A frequent surprise for readers is that HRT does have a bone benefit. Estrogen slows the accelerated bone loss of early menopause, and HRT can be considered for fracture prevention in some people, though it is rarely the sole reason to prescribe it (NHS).

Hormone therapy for cancer vs HRT at a glance

When two treatments share a name, a side-by-side view does more than a paragraph of prose. The table summarizes the mainstream picture drawn from the NCI, NHS and Mayo Clinic resources listed at the end; individual regimens vary.

Feature	Hormone therapy for cancer	HRT (menopausal hormone therapy)
Main goal	Reduce recurrence or slow growth of hormone-sensitive cancer	Relieve menopause symptoms; protect bone in some cases
Effect on hormones	Blocks receptors or lowers estrogen or testosterone	Replaces estrogen, with progestogen if a uterus is present
Who is usually offered it	People with hormone receptor positive breast, prostate or some endometrial cancers	People with bothersome menopause symptoms, typically under 60 or within 10 years of menopause
Typical duration	Often 5 to 10 years for adjuvant breast cancer therapy (NCI); ongoing in advanced disease	Reviewed regularly, often yearly; no fixed maximum, but risk rises with longer combined use (NHS)
Common side effects	Hot flashes, vaginal dryness, joint aches, fatigue, bone thinning, mood change	Breast tenderness, bloating, nausea, headaches, irregular bleeding early on
Key serious risks	Clots and uterine changes with SERMs; bone loss with aromatase inhibitors and ADT; metabolic effects with ADT	Small rise in breast cancer with combined use; clots with oral forms; stroke risk with later start
Effect on hot flashes	Often causes them	Usually relieves them

Two rows deserve a second look. The side effect row shows how tightly the two mirror each other, which is exactly why a cancer survivor’s menopause symptoms are so often severe: the treatment itself is the trigger. The duration row shows why ‘how long will I be on this’ has a very different answer depending on which therapy is being discussed.

Who is usually offered each treatment, and who is usually asked to wait

Cancer endocrine therapy has a clear gatekeeper: the receptor test. Hormone receptor positive tumors qualify; receptor negative tumors do not. Within the qualifying group, oncologists weigh menopausal status, tumor stage, other treatments planned, bone density and clotting history when choosing between drug classes (NCI). People with a history of blood clots, for instance, may be steered away from tamoxifen; those with fragile bones may need extra monitoring on an aromatase inhibitor.

Prostate cancer teams consider androgen deprivation for higher-risk localized disease, often alongside radiotherapy, and for cancer that has spread. It is generally not used for very low-risk disease being monitored with active surveillance, because the side effects would outweigh any benefit (NCI).

HRT has a longer list of pauses. NHS guidance indicates it is usually not offered, or offered only after specialist discussion, to people who:

• have or have had breast cancer, or another hormone-sensitive cancer;
• have untreated high blood pressure;
• have a history of blood clots, particularly if oral estrogen is being considered;
• have liver disease;
• have unexplained vaginal bleeding that has not yet been investigated.

Age and timing matter as well. Someone starting systemic HRT well beyond 60, or more than 10 years after their final period, faces a less favorable balance because of stroke and clot risk, and clinicians may explore alternatives first (Mayo Clinic).

‘Asked to wait’ is sometimes literal. A person with unexplained bleeding will be asked to complete investigations before any estrogen is prescribed. A person mid-way through cancer treatment will be asked to finish that pathway before menopause options are revisited. None of these pauses is a judgment; they are sequencing decisions made by the team that knows the full picture.

Can you be on HRT if you have cancer?

The honest answer is: it depends entirely on which cancer, and the difference is biological rather than bureaucratic.

For hormone receptor positive breast cancer, systemic HRT is generally avoided, during treatment and afterward, because supplying estrogen works against the whole strategy of endocrine therapy. Giving the tumor what the tablets are trying to remove makes little sense, and guidance from the NHS and NCI reflects this. Even receptor negative breast cancer usually prompts caution, since a future cancer could be receptor positive and the evidence is limited.

Low-dose vaginal estrogen occupies a gray zone. Very little reaches the bloodstream, and the 2019 Lancet meta-analysis found little evidence of excess breast cancer risk with topical vaginal products in the general population. Whether it is appropriate for a specific breast cancer survivor, particularly one on an aromatase inhibitor, is a decision for the oncologist, often made jointly with a gynecologist, and practice varies.

For cancers that are not hormone driven, the picture is different. Many people treated for colon, thyroid, skin or blood cancers can discuss HRT on essentially the same terms as anyone else. Some gynecological cancers sit in between: after treatment for certain ovarian or endometrial cancers, HRT may be considered depending on the tumor type and stage.

Treatment-induced menopause adds urgency. Chemotherapy or ovarian suppression can end periods abruptly, sometimes decades early, and the resulting symptoms and bone loss are often harsher than natural menopause. For younger women with non-hormone-sensitive cancers, replacing estrogen until the average age of menopause is frequently discussed precisely because early estrogen loss carries its own health costs (NHS).

Whatever the cancer, this is never a question to settle alone or with a general information sheet. It belongs in the oncology consultation, ideally before symptoms become unbearable.

Does HRT cause breast cancer? What the numbers really show

HRT does not create breast cancer from nothing; it modestly raises the chance that a hormone-sensitive tumor develops or becomes detectable during and for some years after use. How modest depends heavily on the type and duration, and the numbers deserve to be quoted rather than gestured at.

The 2019 individual participant meta-analysis published in the Lancet, pooling data on more than 100,000 women with breast cancer, offers the clearest picture. For a woman of average weight starting HRT at age 50 and using it for 5 years, the estimated breast cancer incidence between ages 50 and 69 was:

• about 6.3 in 100 with no HRT;
• about 6.8 in 100 with estrogen-only HRT, roughly one extra case per 200 users;
• about 7.7 in 100 with estrogen plus intermittent progestogen;
• about 8.3 in 100 with estrogen plus daily progestogen, roughly one extra case per 50 users.

Several patterns emerge from that same analysis. Risk rose with longer use and was higher with combined than estrogen-only preparations. Use for under a year showed little excess. Some excess persisted for more than a decade after stopping, more so after longer use. Vaginal estrogen showed little effect.

Context is what headlines usually strip out. The NHS notes that being overweight, drinking alcohol regularly and having a family history each change breast cancer risk on a comparable or larger scale than HRT for most users. That does not make the HRT contribution trivial; it makes it one factor among several that a woman can weigh.

Ovarian and endometrial cancer belong in the same honest accounting. Estrogen taken without progestogen by someone with a uterus raises endometrial cancer risk, which is why combined preparations exist. NHS guidance also describes a small increase in ovarian cancer risk with HRT that appears to fall after stopping. The absolute numbers are smaller than for breast cancer, but they are not zero.

Why are some doctors cautious about hormone replacement therapy?

Ask a clinician who trained in the early 2000s and you will hear a specific story. A large US trial, the Women’s Health Initiative, was designed to test whether HRT protected the heart. Its combined-therapy arm was stopped early when investigators saw more breast cancers, strokes and clots than expected. Prescriptions fell sharply worldwide, and a generation of doctors absorbed the message that HRT was dangerous (Mayo Clinic).

Later analysis softened that verdict without erasing it. The average trial participant was in her 60s, often more than a decade past menopause, and used one oral combined preparation. Reanalysis suggested that women starting closer to menopause, with a less favorable baseline risk, had a different balance, and that transdermal estrogen (patches or gel) carries less clot risk than tablets. This is the origin of the ‘timing hypothesis’ reflected in current NHS and Mayo Clinic guidance (Mayo Clinic; NHS).

So why the lingering caution? Several reasons hold up:

• The breast cancer signal is real, if modest, and grows with combined use over years.
• Oral estrogen does raise clot and stroke risk, especially in people with other risk factors.
• The person in front of the doctor may have a history that changes everything, from a prior clot to an unrecognized hormone-sensitive tumor.
• Alternatives exist, and some symptoms settle on their own.

Caution is not the same as opposition. Most mainstream guidance now treats HRT as an appropriate choice for many people with troublesome symptoms in early menopause, provided they are informed of the risks and reviewed regularly (NHS). A doctor who hesitates is usually doing the arithmetic for one specific person rather than rejecting the treatment outright. If you feel the conversation has stalled on old assumptions, asking for a referral to a clinician with a menopause interest is a reasonable step.

Side effects of hormone therapy for cancer: the disadvantages nobody should downplay

Endocrine therapy is often described as gentler than chemotherapy. Compared head to head, that is fair. Lived over five or ten years, it is a different kind of hard, and people deserve to hear that plainly.

Across both breast and prostate treatment, the shared theme is an engineered hormone deficiency. The NCI lists hot flashes, night sweats, fatigue, reduced libido, vaginal dryness in women, erectile difficulty in men, mood changes and weight gain as common effects. These are not signs the treatment is failing; they are signs it is doing what it was built to do.

Class-specific issues differ:

• Tamoxifen acts like weak estrogen on the womb lining, slightly raising endometrial cancer risk, and increases the chance of blood clots. Unexpected vaginal bleeding on tamoxifen is always investigated (NCI).
• Aromatase inhibitors commonly cause joint stiffness and aching, particularly in the hands, and accelerate bone thinning, so bone density monitoring is routine (NCI).
• Androgen deprivation therapy can reduce muscle mass, increase body fat, thin bones and affect blood sugar and cholesterol. Breast tenderness and reduced energy are also reported (NCI).

The most under-discussed disadvantage is adherence. When a tablet makes each day slightly worse and the benefit is invisible, stopping early is tempting, and studies summarized by the NCI show a meaningful share of people do not complete the intended course. That is why side effects should be reported rather than endured; oncologists can often adjust the approach, switch classes or add supportive care, and a modified plan taken consistently usually serves a patient better than an ideal plan abandoned.

None of this is an argument against treatment. It is an argument for entering it with clear eyes and a low threshold for speaking up.

What the first weeks and months usually look like on either therapy

Neither treatment announces itself dramatically. Both unfold over weeks, and knowing the typical arc helps people distinguish expected adjustment from something that needs a call.

Starting endocrine therapy for breast cancer. Most people begin within weeks of finishing surgery or radiotherapy. Hot flashes and sleep disturbance often appear in the first month as estrogen signaling drops. Joint aches on an aromatase inhibitor tend to build over the first few months rather than arrive immediately. A first review commonly happens within three months to check tolerance, then at regular intervals, with bone density scans scheduled according to the drug class and baseline risk (NCI). The NCI’s typical adjuvant course of 5 to 10 years means this becomes a background rhythm of daily tablets and periodic reviews.

Starting androgen deprivation therapy. Some injection types cause a brief initial testosterone surge before levels fall, so a short course of blocking tablets may be used at the start; your team will explain if this applies. Hot flashes and fatigue typically follow over the first few weeks. Blood tests track hormone levels and prostate-specific antigen, a protein used to monitor prostate cancer activity (NCI).

Starting HRT. The NHS notes that it can take a few weeks to feel the benefit and that clinicians usually suggest continuing for about 3 months before judging whether a preparation suits you. Early breast tenderness, bloating and irregular bleeding are common and often settle. Persistent bleeding after the first months, or bleeding that starts after a long settled stretch, warrants investigation. Reviews are typically yearly once stable (NHS).

A practical tip that applies to all three: keep a simple symptom log for the first quarter. A dated note of flashes, sleep, mood and aches makes the follow-up appointment far more productive than memory alone, and it helps your prescriber see patterns you might dismiss.

HRT after breast cancer: how menopause symptoms are usually managed without estrogen

For the many people who cannot take systemic estrogen after breast cancer, the phrase ‘just cope with it’ is not a plan. Mainstream guidance offers a toolkit, and it is worth knowing the categories so you can ask about them by name.

Non-hormonal prescription options include certain antidepressant classes that dampen hot flashes at lower intensities than used for mood, a nerve-pain medicine class that can reduce night sweats, and a blood pressure medicine class with a modest effect on flushing. Newer medicines that act on the brain’s temperature center have also emerged. Each carries its own side effects and some interact with tamoxifen, which is why choice rests with the oncologist and prescriber (NCI; NHS).

For vaginal dryness and painful sex, regular non-hormonal moisturizers and lubricants are first-line and help many people. If they fall short, the low-dose vaginal estrogen question from earlier returns to the table for individual discussion.

Behavioral and lifestyle measures have evidence behind them, if not dramatic effect sizes. Cognitive behavioral therapy adapted for menopause reduces how much hot flashes disrupt sleep and mood. Layered clothing, cooler bedrooms, limiting alcohol and identifying personal triggers such as caffeine or spicy food help some people. Regular weight-bearing exercise addresses bone loss, mood and fatigue at once (NHS).

Supplements deserve a word of caution. Plant estrogens such as soy isoflavones and red clover act weakly on the same receptors endocrine therapy is blocking, and the evidence that they relieve symptoms is mixed; oncologists often advise avoiding concentrated forms after hormone-sensitive cancer. Black cohosh has inconsistent trial results and rare reports of liver effects. Mention any supplement you are taking or considering, because ‘natural’ does not mean inert (NIH).

The goal here is not to match HRT but to reclaim sleep, comfort and function within the limits your diagnosis sets.

What people often get wrong about hormone therapy for cancer vs HRT

Some misunderstandings surface so often in clinic corridors that correcting them is a public service.

‘My cancer hormone therapy is the same thing my friend takes for menopause.’ It is the opposite. One removes hormone signaling, the other restores it. Sharing experiences can still be comforting, but the side effect profiles and precautions do not transfer.

‘HRT causes breast cancer, full stop.’ The evidence shows a modest, duration-dependent rise in risk, larger with combined preparations and small or absent with short courses and vaginal products. It is a factor to weigh, not a verdict (Lancet 2019).

‘Estrogen-only and combined HRT carry the same risk.’ They do not. The progestogen component drives most of the breast cancer excess, while estrogen-only use is restricted to people without a uterus because of endometrial risk (Lancet 2019; NHS).

‘Feeling fine means the cancer treatment isn’t needed.’ Adjuvant therapy targets cells that cannot be seen or felt. Absence of symptoms is the expected state, not evidence the tablets are pointless (NCI).

‘Hot flashes on tamoxifen mean the drug is failing.’ They are a sign estrogen signaling is being interrupted. Report them so they can be managed, not as evidence of ineffectiveness.

‘Men do not get hormone therapy.’ Androgen deprivation is a cornerstone of prostate cancer care, and men experience many of the same effects women describe, including flashes, bone loss and mood change (NCI).

‘Bioidentical or compounded hormones avoid the risks.’ Regulated HRT products already use hormones structurally identical to the body’s own. Custom-compounded mixtures lack standardized testing and are not shown to be safer (Mayo Clinic).

‘Once I stop HRT the risk vanishes immediately.’ Some excess risk persists for years after longer use, which is one more reason regular review matters (Lancet 2019).

Questions to ask your care team before starting either treatment

Appointments run short and questions evaporate under pressure. Writing them down beforehand changes the dynamic. These are the ones that tend to unlock the most useful conversations.

If you are being offered hormone therapy for cancer:

• What were my receptor results, and how strongly do they predict benefit from this treatment?
• Which drug class are you recommending, and why that one for me rather than the alternatives?
• How long do you anticipate I will take it, and what would change that plan?
• What side effects are most likely with this class, and which ones should prompt a call rather than waiting for a review?
• Will I need bone density scans, blood tests or gynecological checks, and how often?
• If side effects become difficult, what are my options besides stopping?
• How will this interact with other medicines or supplements I take?

If you are considering HRT:

• Given my personal and family history, where does my risk balance fall?
• Would a patch or gel suit me better than tablets, and why?
• Do I need a progestogen, and in what pattern?
• How soon should I expect to notice benefit, and when will we review?
• What bleeding pattern is normal early on, and what is not?
• How will this affect my breast screening and what should I tell the radiographer?
• What would make you want me to stop or change preparation?

If you have had cancer and are struggling with menopause symptoms:

• Is my cancer type hormone sensitive, and what does that mean for my options?
• Which non-hormonal treatments are compatible with my current medicines?
• Is low-dose vaginal estrogen something you would consider for me, and who should be part of that decision?

Bring a companion if you can. A second set of ears catches the answers you miss while forming the next question.

When to call your doctor

Most side effects of both therapies are uncomfortable rather than dangerous, and belong in the notes for your next review. A smaller group should not wait. Contact your care team the same day, or seek emergency care, for any of the following.

Possible blood clot or stroke, relevant to tamoxifen and to oral HRT in particular:

• sudden swelling, warmth or pain in one calf or thigh;
• sudden shortness of breath, sharp chest pain or coughing up blood;
• sudden weakness or numbness on one side, facial droop, slurred speech or a severe headache unlike any before.

Gynecological warning signs:

• any vaginal bleeding after menopause that is new, heavy or persists beyond the early adjustment period on HRT;
• any vaginal bleeding while taking tamoxifen, since it can signal changes in the womb lining (NCI).

Breast changes on any therapy: a new lump, skin dimpling, nipple discharge or inversion, or a change in size or shape (NHS).

Specific to androgen deprivation therapy: new bone pain, difficulty passing urine or numbness and weakness in the legs, which can indicate pressure on the spinal cord and needs urgent assessment (NCI).

Any therapy: yellowing of the skin or eyes, severe abdominal pain, a rash with fever, or a mood change that includes thoughts of harming yourself.

Do not stop a prescribed cancer medicine on your own because of a frightening symptom; call and describe it, and let the team decide whether to pause. Equally, do not restart or adjust HRT after a red-flag event until you have been assessed. The judgment about what a symptom means, and what to do about it, sits with the clinicians who know your history and can examine you.

Frequently asked questions

Can you be on HRT if you have cancer?

It depends on the cancer. Systemic HRT is generally avoided after hormone receptor positive breast cancer because estrogen can fuel that tumor type. After many non-hormone-driven cancers, such as colon, thyroid or blood cancers, HRT can often be discussed on ordinary terms. Some gynecological cancers fall in between. The decision belongs with your oncology team, who know the tumor biology and your wider history.

Why are doctors against hormone replacement therapy?

Most are not against it; many are cautious because of a large trial in the early 2000s that showed more breast cancers, clots and strokes in older women on oral combined HRT. Later analysis found a better balance for people starting near menopause, especially with skin patches or gel. Current NHS and Mayo Clinic guidance supports HRT for many people with troublesome symptoms after an individual risk discussion.

Is HRT worth the cancer risk?

That is a personal calculation, not a universal one. For 5 years of combined HRT from age 50, the Lancet 2019 analysis estimated roughly one extra breast cancer per 50 users by age 69; for estrogen-only, roughly one per 200. Against that sit relief from severe symptoms, better sleep and bone protection. Your own history, symptom burden and preferences decide where the balance falls, discussed with your prescriber.

What are the disadvantages of hormone therapy for cancer?

The main disadvantages are living for years in an induced low-hormone state: hot flashes, fatigue, reduced libido, joint aches, mood change and bone thinning. Tamoxifen adds clot and endometrial risks; aromatase inhibitors and androgen deprivation accelerate bone loss; androgen deprivation can affect muscle, fat and blood sugar. Reporting side effects early lets the team adjust the approach rather than lose the benefit through early stopping.

Does HRT cause breast cancer or just raise the risk?

It raises the risk modestly rather than causing cancer outright. The effect depends on type and duration: combined preparations carry more risk than estrogen-only, risk grows with years of use, short courses under a year show little excess, and vaginal estrogen shows little effect. Some excess persists for years after stopping longer courses. Weight, alcohol and family history shift risk on a comparable scale.

Is hormone therapy for cancer the same as chemotherapy?

No. Chemotherapy kills rapidly dividing cells directly and is usually given in cycles over months. Hormone therapy interferes with a growth signal that hormone-sensitive tumors depend on, is typically taken daily for years, and has a different side effect profile centered on hormone deficiency rather than hair loss or low blood counts. Many people receive both, in sequence, depending on tumor features.

How long do you take hormone therapy after breast cancer?

The NCI describes adjuvant endocrine therapy as typically lasting 5 to 10 years, with the longer end considered for people at higher risk of recurrence. For advanced disease, treatment continues while it is controlling the cancer and remains tolerable. Your oncologist sets and revisits the duration based on tumor stage, receptor results, side effects and newer evidence as it emerges.

Can men have HRT and hormone therapy for cancer?

Men can receive both, though in different contexts. Androgen deprivation therapy for prostate cancer lowers testosterone and is a cornerstone of treatment for higher-risk or advanced disease. Testosterone replacement is used for diagnosed testosterone deficiency in men without prostate cancer. The two are opposites, and testosterone replacement is generally avoided in men with active prostate cancer for the same reason estrogen is avoided after breast cancer.

What can I use for hot flashes if I cannot take HRT after cancer?

Options include certain antidepressant, nerve-pain and blood pressure medicine classes that reduce flushing, newer non-hormonal drugs acting on the brain’s temperature center, cognitive behavioral therapy adapted for menopause, and practical measures such as cooler rooms and trigger avoidance. Some medicines interact with tamoxifen, so choice rests with your oncologist. Concentrated plant estrogen supplements are often discouraged after hormone-sensitive cancer.

Is vaginal estrogen safe after breast cancer?

The evidence is reassuring in the general population, where the Lancet 2019 analysis found little excess breast cancer risk with vaginal products, but data specific to survivors are limited, particularly for those on aromatase inhibitors. Many oncologists consider it when non-hormonal moisturizers and lubricants fail, weighing symptom severity against the small absorbed amount. It is an individual decision made with your cancer team, not a general rule.

References

• NHS: Benefits and risks of hormone replacement therapy (HRT)
• MedlinePlus: Hormone Replacement Therapy

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.